Family & Pregnancy

Preeclampsia Testing

Genetic and biomarker-based screening for early risk assessment of preeclampsia during pregnancy.

 Contact us

Description

The iLab Medical Preeclampsia Risk Assessment is a biomarker-based screening test of Placental Growth Factor (PlGF) designed for early identification of women at increased risk of developing preeclampsia. The test is intended for use during the first trimester of pregnancy and supports individualized obstetric risk stratification.

Preeclampsia is a multisystem hypertensive disorder of pregnancy characterized by new-onset hypertension and organ dysfunction after 20 weeks of gestation. It is associated with significant maternal and fetal morbidity and mortality, including preterm birth, fetal growth restriction, placental insufficiency, and long-term cardiovascular complications.

Early identification of high-risk pregnancies enables timely implementation of preventive strategies and closer clinical monitoring.

The analysis is performed in co-operation with Revvity on Delphia Xpress with the PlGF 1-2-3 kit, used in the ASPRE-study.

 

 

Benefits

Enables early risk assessment of preeclampsia
Identifies high-risk pregnancies before symptom onset
Supports individualized pregnancy monitoring
Complements established screening and care programs
Based on validated biomarkers and laboratory methodologies
Integrates easily into clinical and research workflows

Process

Sample collection is performed via a venous blood draw, typically between gestational weeks 10+0 and 13+6. The sample is collected during a routine clinical visit and does not require any follow-up appointments. Blood handling follows standardized laboratory procedures.

Following sample collection, serum is processed and analyzed in the laboratory, focusing on biomarkers associated with early preeclampsia risk. The analysis is conducted using controlled and quality-assured methods.

The results are used for risk stratification and may support clinical follow-up, preventive measures, or enhanced pregnancy surveillance according to local clinical guidelines.

Specimen Requirements

Sample Type

  • Maternal venous blood

Collection Tube

  • Yellow-top tube (serum separator tube – SST)

Collection Volume

  • 3–5 mL whole blood

Handling Instructions

  • Allow blood to clot at room temperature
  • Centrifuge according to standard laboratory protocol
  • Separate serum promptly
  • Avoid hemolysis
  • Store and transport according to laboratory guidelines
  • NB! Need cold chain transport

Improper sample handling may affect biomarker stability and test accuracy.

Indications for Testing

  • Routine first-trimester screening
  • History of preeclampsia in prior pregnancy
  • Chronic hypertension
  • Diabetes mellitus (Type 1 or Type 2)
  • Renal disease
  • Autoimmune disorders
  • Multiple gestation
  • Advanced maternal age
  • Obesity or high BMI

Limitations

  • This is a screening test and does not establish a definitive diagnosis of preeclampsia.
  • Results should be interpreted within the full clinical context.
  • Ongoing obstetric monitoring remains essential regardless of screening outcome.

How it works

The blood sample is centrifuged and serum is separated prior to analysis. Biomarker levels are measured using laboratory platforms optimized for reproducibility and clinical precision. Results are reviewed by a specialist laboratory.

A structured report is generated and delivered to the ordering healthcare provider or clinic. The information is used as clinical decision support in ongoing pregnancy management and is communicated to the patient according to the clinic’s established procedures.

The test measures validated biochemical markers associated with placental function and angiogenic balance. Abnormal biomarker levels reflect impaired placentation and endothelial dysfunction, which are central to the pathophysiology of preeclampsia.

Results are interpreted in conjunction with:

  • Maternal clinical risk factors
  • Blood pressure measurements
  • Gestational age
  • Relevant obstetric history

Risk calculation models may incorporate maternal age, BMI, parity, previous preeclampsia, chronic hypertension, diabetes, and other contributing factors.

Clinical Utility

  • First-trimester risk stratification for early-onset and preterm preeclampsia
  • Identification of patients who may benefit from prophylactic low-dose aspirin therapy
  • Supports personalized antenatal surveillance plans
  • Enables early referral to high-risk obstetric care when indicated
  • Reduces maternal and perinatal complications through preventive management

Early risk assessment significantly improves clinical outcomes by allowing intervention before disease onset.

Preeclampsia Testing
Consultation for clinics